Neurotype Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Seed
- Investors
-
6
Neurotype General Information
Description
Developer of an electroencephalography-based neurotechnology platform designed to support recovery from substance use disorders by measuring brain responses associated with craving. The company's platform offers non-invasive electroencephalography, visual event-related potential analysis, clinical decision support reports, and closed-loop neurofeedback, enabling clinicians and treatment specialists to measure craving-related neural activity and guide targeted interventions for sustained recovery.
Contact Information
Website
www.neurotype.ioCorporate Office
- 4610 East Lake Street
- Suite 306
- Minneapolis, MN 55406-2364
- United States
Corporate Office
- 4610 East Lake Street
- Suite 306
- Minneapolis, MN 55406-2364
- United States
Neurotype Timeline
Neurotype Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Seed Round | 16-Mar-2026 | Completed | Generating Revenue | |||
| 11. Grant | 01-Oct-2023 | Completed | Generating Revenue | |||
| 10. Grant | 01-Jul-2023 | Completed | Generating Revenue | |||
| 9. Grant | 19-Oct-2022 | Completed | Generating Revenue | |||
| 8. Grant | 10-Oct-2022 | Completed | Generating Revenue | |||
| 7. Grant | 28-Feb-2022 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 15-Apr-2021 | Completed | Generating Revenue | |||
| 5. Grant | 15-Sep-2020 | Completed | Generating Revenue | |||
| 4. Grant | 15-Jul-2020 | $29.7K | $405K | Completed | Startup | |
| 3. Accelerator/Incubator | 01-Jan-2020 | $405K | $405K | Completed | Startup |
Neurotype Patents
Neurotype Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12343157-B2 | Assessing motivated attention with cue reactivity | Active | 14-Apr-2020 | ||
| US-20210315508-A1 | Assessing motivated attention with cue reactivity | Active | 14-Apr-2020 | ||
| US-20250311961-A1 | Assessing motivated attention with cue reactivity | Pending | 14-Apr-2020 | A61B5/378 |
Neurotype Signals
Neurotype Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Frontline Ventures | Venture Capital | Minority | ||
| Techstars | Accelerator/Incubator | Minority | ||
| Minnesota Department of Employment and Economic Development | Government | |||
| National Institutes of Health | Government | |||
| National Institute on Drug Abuse (NIDA) | Government |
Neurotype FAQs
-
When was Neurotype founded?
Neurotype was founded in 2019.
-
Where is Neurotype headquartered?
Neurotype is headquartered in Minneapolis, MN.
-
What is the size of Neurotype?
Neurotype has 2 total employees.
-
What industry is Neurotype in?
Neurotype’s primary industry is Monitoring Equipment.
-
Is Neurotype a private or public company?
Neurotype is a Private company.
-
What is Neurotype’s current revenue?
The current revenue for Neurotype is .
-
How much funding has Neurotype raised over time?
Neurotype has raised $460K.
-
Who are Neurotype’s investors?
Frontline Ventures, Techstars, Minnesota Department of Employment and Economic Development, National Institutes of Health, and National Institute on Drug Abuse (NIDA) are 5 of 6 investors who have invested in Neurotype.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process